Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer

NCT02820961 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.

NCT NCT02820961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02820961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer
Lead sponsor
Syndax Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
June 29, 2016
Completion date
July 12, 2021
Enrollment
61 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, estrogen receptor positive breast cancer